Basic Search
|
Summaries
|
Advanced Search
Violation Tracker Current Parent Company Summary
Current Parent Company Name: Glenmark Pharmaceuticals
Ownership Structure: publicly traded
Headquartered in: India
Major Industry: pharmaceuticals
Specific Industry: generic pharmaceuticals
Penalty total since 2000: $85,637,300
Number of records: 5
Top 5 Offense Groups (Groups Defined) | Penalty Total | Number of Records |
competition-related offenses | $44,000,000 | 2 |
government-contracting-related offenses | $38,750,000 | 2 |
healthcare-related offenses | $2,887,300 | 1 |
Top 5 Primary Offense Types | Penalty Total | Number of Records |
price-fixing or anti-competitive practices | $44,000,000 | 2 |
False Claims Act and related | $38,750,000 | 2 |
HHS civil monetary penalties | $2,887,300 | 1 |
Notes: Parent-subsidiary linkages are based on relationships current as of the latest revision listed in the
Update Log, which may vary from what was the case when a violation occurred. The penalty totals are adjusted to account for the fact that the individual entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. The totals are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the list below.
Links: For a summary of this company's regulatory penalties in more than 50 other countries, see its Violation Tracker Global summary page
here.
Individual Penalty Records:
Click on the company or penalty amount for more information on each case.
Company | Primary Offense Type | Year | Agency | Penalty Amount |
Glenmark Pharmaceuticals Inc., USA | price-fixing or anti-competitive practices | 2023 | DOJ_ANTITRUST | $30,000,000 |
Glenmark Pharmaceuticals Inc. | False Claims Act and related | 2024 | DOJ_CIVIL | $25,000,000 |
Glenmark Pharmaceuticals | price-fixing or anti-competitive practices | 2023 | private lawsuit-federal | $14,000,000 |
Glenmark Generics Inc. | False Claims Act and related | 2015 | TX-AG | $13,750,000 |
Glenmark Pharmaceuticals, Inc. | HHS civil monetary penalties | 2015 | HHSOIG | $2,887,300 |